BioNTech SE Buys into CureVac N.V.
| Field | Detail |
|---|---|
| Company | Curevac N.V. |
| Form Type | 6-K |
| Filed Date | Jun 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, biotechnology, partnership
TL;DR
BioNTech SE is buying into CureVac N.V. as of June 12, 2025.
AI Summary
On June 12, 2025, BioNTech SE entered into a Purchase Agreement with CureVac N.V. as the buyer. This filing is a Form 6-K report for the month of June 2025, submitted by CureVac N.V.
Why It Matters
This agreement signifies a potential strategic partnership or investment between two significant players in the biotechnology sector, which could impact future developments in their respective pipelines.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, suggesting a significant transaction that could carry inherent risks related to integration, market reception, or regulatory hurdles.
Key Players & Entities
- BioNTech SE (company) — Buyer in the Purchase Agreement
- CureVac N.V. (company) — Registrant and party to the Purchase Agreement
- June 12, 2025 (date) — Date of the Purchase Agreement
FAQ
What is the nature of the Purchase Agreement between BioNTech SE and CureVac N.V.?
The filing states that BioNTech SE is the 'Buyer' in a Purchase Agreement with CureVac N.V., entered into on June 12, 2025.
What is the filing type and reporting period for CureVac N.V.?
This is a Form 6-K report for the month of June 2025.
What is CureVac N.V.'s principal executive office address?
CureVac N.V.'s principal executive office is located at Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany.
What is CureVac N.V.'s central index key (CIK)?
CureVac N.V.'s central index key is 0001809122.
What is the SEC file number for CureVac N.V.?
CureVac N.V.'s SEC file number is 001-39446.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 16, 2025 regarding CureVac N.V..